OncoMatch/Clinical Trials/NCT07066397
A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
Is NCT07066397 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including ARM011 and Fludarabine for acute lymphoblastic leukemia.
Treatment: ARM011 · Fludarabine · Cyclophosphamide — This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard treatment
Refractory to or relapsed after current standard treatment
Cannot have received: anti-CD19 therapy
Exception: blinatumomab
Prior anti-CD19 therapy (other than blinatumomab)
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify